Associate Vice President Pain Early Development

Role: The Global Lead, Pain Early Development, provides senior medical and scientific leadership for Lilly's early-phase pain portfolio, overseeing clinical development from first patient dose through Phase 2 or key decision points. Responsibilities include defining and executing integrated clinical strategies, establishing governance frameworks, managing portfolio health and pipeline gaps, and representing Lilly externally to regulatory bodies and scientific communities. The role involves shaping external innovation efforts, leading collaborations, and driving early portfolio decision-making, with a focus on innovative modalities such as RNA silencing and gene therapy. It also entails engaging with global regulators, overseeing scientific data disclosures, and managing program governance and risk assessment. Leadership responsibilities include building and developing cross-functional teams, fostering scientific and strategic alignment across R&D, Medical, and Commercial functions, and establishing capabilities to strengthen Pain portfolio development. Qualifications: MD with board eligibility or certification in a relevant specialty, with 12+ years in analgesic clinical development or pharmaceutical medicine. Preferred experience includes deep therapeutic expertise in pain, early development strategy, and innovation in neuroscience. The position requires strong leadership, influence, and communication skills, with willingness to travel domestically and internationally. High-value specifics involve focus on pain, early-stage development, novel modalities, external partnerships, regulatory engagement, and cross-disciplinary collaboration. The work setup is not explicitly stated but involves strategic leadership within a global pharmaceutical context.